Letrozol-Ct Abz-Pharma

Letrozole, the active ingredient in Letrozol-Ct Abz-Pharma, is an aromatase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women, where it lowers estrogen levels that can drive tumor growth.

GNH USA supplies Letrozol-Ct Abz-Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, with a focus on quality and regulatory compliance.

Letrozole is used in the management of hormone‑dependent breast cancer, targeting estrogen‑driven tumor pathways.

- Early‑stage hormone receptor‑positive breast cancer: helps prevent recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer: slows disease progression in advanced cases. - Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen‑driven tumor growth.

Adverse reactions may occur with letrozole therapy.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching in knees, hips, or shoulders. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Severe liver injury: jaundice, dark urine, elevated liver enzymes. - Bone fracture: increased risk of osteoporosis‑related breaks. - Thromboembolic events: deep vein thrombosis or pulmonary embolism.

Before initiating letrozole, several safety considerations should be reviewed.

- Pregnancy: contraindicated (Category X); teratogenic risk. - Breastfeeding: not recommended; drug may pass into milk. - Bone health: monitor bone mineral density, consider calcium/vitamin D supplementation. - Liver function: assess hepatic status; dose adjustment may be needed. - Drug interactions: review concomitant medications for potential CYP2A6 involvement. - Store at ambient temperature: keep in original container, protect from moisture and light.

Letrozole may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Estrogen replacement therapy: may counteract letrozole's estrogen‑lowering effect. - Strong CYP2A6 inhibitors (e.g., fluvoxamine): can raise letrozole plasma levels. - Tamoxifen: antagonistic action, diminishing therapeutic benefit.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR and bleeding risk. - Diuretics: potential electrolyte disturbances. - SSRIs (e.g., fluoxetine): may alter letrozole metabolism.